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time point. In multiple regression analysis, gender was an 
independent determinant of ERI (b = 0.34; p < 0.05).
Conclusions Despite higher dialysis adequacy, Hb concen-
tration in women treated with PD is significantly lower, and 
the ability to correct it impaired, as compared to men.
Keywords Peritoneal dialysis · Gender · Dialysis 
adequacy · Anaemia · Erythropoiesis-stimulating agents
Introduction
 Anaemia is a constant complication of end-stage renal 
disease (ESRD). Driven mainly by a relative deficit in 
erythropoietin, it has an important impact on patient’s 
physical condition and quality of life. Vast majority of 
patients receive erythropoiesis-stimulating agents (ESA) 
to partially correct it. The target haemoglobin (Hb) con-
centrations are set constant, regardless of the patient’s sex 
[1]. This stays in contrast to the situation in the general 
population where Hb level is typically higher in men than 
in women. By current criteria, women are considered to be 
anaemic if their haemoglobin is less than 11.5 or 12.0 g/dl, 
while in males the threshold is set at 13.0 or 13.5 g/dl [2]. 
These gender-associated disparities in Hb concentration 
are believed to be due to several factors including sex hor-
mones, iron deficiency due to menstrual losses, and per-
haps poor nutritional intake [2]. These factors are, to some 
extent, absent in peritoneal dialysis (PD) patients. How-
ever, it is not clear whether this would result in equal Hb 
levels and similar ESA requirements in men and women 
on PD.
One of the major determinants of anaemia severity and 
ESA responsiveness is dialysis adequacy [3]. Patients with 
an inadequate dialysis dose are resistant to ESA, and their 
Abstract 
Purpose In the general population, haemoglobin (Hb) con-
centration is higher in men than in women. However, tar-
get Hb levels in dialysis patients are set constant regardless 
of the patient’s sex. The aim of this study was to evaluate 
Hb concentration and the use of erythropoiesis-stimulating 
agents (ESA) in peritoneal dialysis (PD) patients taking 
gender and dialysis adequacy into account.
Methods The study comprised two parts. The first was a 
cross-sectional analysis of Hb and ESA in 2180 prevalent 
PD patients. The second included 88 incident PD patients, 
followed for 36 months. During this time, the major param-
eters recorded at 12-month intervals included: Hb con-
centration, weekly ESA, total, renal, and peritoneal Kt/V. 
Erythropoietin resistance index (ERI) was calculated as the 
ratio between ESA dose and achieved Hb.
Results In prevalent PD patients, Hb concentration was 
significantly lower in women, (11.2 ± 1.4 vs. 11.5 ± 1.6 g/
dl; p < 0.001), despite higher doses of ESA (2691 ± 1821 
vs. 2344 ± 1422; p = 0.001). Hb concentrations were 
related to dialysis adequacy in both cohorts. However, 
despite significantly higher Kt/V, women were character-
ized by a lower Hb level. In incident patients, this associa-
tion was present throughout the observation period, while 
the ESA dose in women was significantly higher at every 
 * Monika Lichodziejewska-Niemierko 
 lichotek@gumed.edu.pl
1 Department of Nephrology, Transplantology and Internal 
Medicine, Medical University of Gdan´sk, Gdan´sk, Poland
2 Department of Hygiene and Epidemiology, Medical 
University of Gdan´sk, Gdan´sk, Poland
3 Department of Palliative Medicine, Medical University 
of Gdan´sk, Gdan´sk, Poland
 Int Urol Nephrol
1 3
target Hb is harder to reach [4]. In haemodialysis, there is 
an inverse relationship between the achieved Kt/V and ESA 
dose, while increasing the dialysis dose is associated with 
an increase in haematocrit level [5, 6].
The primary aim of the present study was to evaluate 
potential associations between gender and Hb concentra-
tions and ESA demand in prevalent as well as in incident 
PD patients. The second objective was to evaluate the 
potential associations between dialysis adequacy, assessed 
by the Kt/V, and Hb levels, as well as responsiveness to 
ESA treatment, taking gender into account.
Materials and methods
The first part of the study was performed on the basis of the 
national PD Registry, on 2180 prevalent PD patients. This 
was a cross-sectional evaluation of Hb concentration and 
ESA dose in men and women treated with PD. Obtained 
data also included the prevalence of co-morbidities and the 
total weekly Kt/V. The Polish PD Registry was established 
by the National Consultant in Nephrology, and it replaced 
PD survey in which aggregated data were gathered from 
all PD centres in Poland. The basic individual patient and 
treatment data are collected by the Registry from all the PD 
centres in Poland on an annual basis. The diagnosis of co-
morbidities was based on the information provided by the 
centres.
The second part was undertaken to get deeper insight 
into the mechanisms relating gender and dialysis adequacy 
to anaemia and ESA requirements of PD subjects. It was 
designed as a retrospective observational evaluation. All 
patients who initiated PD as their first renal replacement 
therapy (RRT) in a nephrology department of a large uni-
versity-based hospital in the period between 2009 and 2013 
were included. The typical dialysis prescription at baseline 
was four exchanges per day with a 2000 ml low-glucose 
solution for patients treated with continuous ambulatory 
PD (CAPD), and 10,000 ml of low-glucose fluid overnight 
for subjects who started on automated PD (APD; Fresenius, 
Bad Homburg, Germany). All patients were followed until 
death, kidney transplantation, transfer to haemodialysis, or 
the end of the follow-up period, with a maximum follow-
up of 36 months since the start of dialysis. During this 
time, the evaluated parameters were recorded at 12-month 
intervals. These included: Hb concentration, weekly ESA 
dosage per kg of body mass, total weekly Kt/V, renal Kt/V, 
and peritoneal Kt/V. Most patients received erythropoie-
tin-beta as their ESA (NeoRecormon; Roche Pharma AG; 
Grenzach-Wyhlen, Germany). For comparisons, the weekly 
dose of ESA in patients taking other ESA than erythropoi-
etin-beta was converted into erythropoietin-beta units. The 
erythropoietin resistance index (ERI) was calculated as the 
ratio between the weekly weight-adjusted ESA dose and 
Hb concentration.
All biochemical analyses were performed using routine 
methods at the local laboratory. Apart from the abovemen-
tioned, they included: urea, creatinine, albumin, C-reactive 
protein (CRP), iron, ferritin, transferrin saturation. Diag-
nosis of cardiovascular disease (CVD), diabetes mel-
litus (DM), and arterial hypertension was made based on 
patients’ medical records. Glomerular filtration rate (GFR) 
was estimated based on the MDRD equation.
Protocol of the study received approval from the Local 
Bioethics Committee. Results are expressed as percent-
ages (for categorical variables), mean and standard devia-
tion, or median and interquartile range, as appropriate. The 
assumption of normality was verified with the Kolmogo-
rov–Smirnov test. A p value <0.05 was considered to be 
statistically significant. Comparisons between two groups 
were assessed with a Student’s t test or a Mann–Whit-
ney test, as appropriate. To assess correlations among the 
evaluated variables, Pearson’s correlation coefficient (r) 
was used. Independent associations among variables were 
assessed with stepwise multiple regression analysis. Statis-
tical processing of the results was performed with the use 
of the statistical software STATISTICA PL v 12.0 (Statsoft, 
Kraków, Poland).
Results
The cross-sectional evaluation of the data from the national 
PD Registry was based on 2180 prevalent PD patients. The 
group included 1023 women and 1157 men. Their clinical 
characteristics are presented in Table 1. Men were char-
acterized by a higher prevalence of co-morbidities and a 
poorer dialysis adequacy, as compared to women. In the 
studied population, hypertensive patients had a lower Hb 
concentration, when compared to subjects with normal 
blood pressure (11.2 ± 1.6 vs. 11.4 ± 1.8 g/dl; p < 0.05). 
Lower Hb in hypertensive subjects did not result from 
Table 1  Baseline characteristics of the 2180 prevalent PD patients
DM diabetes mellitus, GN primary glomerulonephritis, ADPKD auto-
somal dominant polycystic kidney disease
Men (n = 1157) Women (n = 1023) p value
Age 61 (48–71) 61 (47–72) NS
DM (%) 33 29 0.03
Hypertension (%) 83 75 0.001
GN (%) 20 15 0.001
ADPKD (%) 4 6 0.03
Kt/V 2.25 ± 0.67 2.47 ± 0.74 0.001
Albumin (g/l) 32.1 ± 13.8 31.4 ± 13.9 NS
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drugs affecting the renin–angiotensin–aldosterone system 
(RAAS), as Hb level was identical in patients with and 
without RAAS blockers (11.3 ± 1.6 vs. 11.3 ± 1.7 g/dl, 
respectively). There was a weak but significant positive 
association between the total Kt/V and Hb level (r = 0.13; 
p < 0.05), and a considerable negative association between 
the achieved Kt/V and the required ESA dose (r = −0.19; 
p < 0.05). When Hb concentration was evaluated tak-
ing gender into account, it turned out to be significantly 
higher in men than in women (11.5 ± 1.6 vs. 11.2 ± 1.4 g/
dl; p < 0.001). In multiple regression analysis, gender was 
among the independent predictors of Hb level, together 
with Kt/V, presence of diabetes mellitus and hyperten-
sion (combined R2 = 0.31, p < 0.001). Percentage of men 
treated with ESA was significantly lower than women (69 
vs. 76%; p < 0.001), and similarly, the average weekly dose 
of ESA was lower, as compared to women (2344 ± 1422 
vs. 2691 ± 1821; p = 0.001).
The second part of the analysis included a total of 88 
patients who started PD treatment as their initial RRT in 
2009–2013. This group comprised 53 men and 35 women. 
The primary kidney disease was primary glomerulone-
phritis in 25 patients (28%), diabetes mellitus in 15 sub-
jects (17%), hypertensive nephropathy in 5 (6%), ADPKD 
in 5 (6%), other and unknown in 38 patients (43%). The 
prevalence of particular primary kidney diseases was 
comparable between men and women. Dialysis modal-
ity included CAPD in 67 patients (76%) and APD in 21 
subjects (24%) and did not differ between genders. The 
baseline clinical characteristics of the studied cohort 
are shown in Table 2. Men were slightly older and had 
a higher prevalence of co-morbidities, as compared to 
women. At baseline, they also had an increased CRP, 
phosphate, and their body mass index (BMI) was signifi-
cantly higher than in women. Neither of these variables 
turned out as significant predictors of Hb concentration 
in the multivariate analysis. The iron status was similar 
in both groups. Out of 53 men included in the study, ten 
(19%) were on oral iron supplementation with a standard 
dose of 100 mg of iron sulphate per day. In women, five 
(14%) received iron at baseline (p = NS). The percent-
age of patients prescribed iron increased during the study 
period and reached 47% in men and 55% in women after 
3 years of follow-up (p = NS).
Men started dialysis at a higher eGFR, although this 
difference was not statistically significant (9.7 ± 3.8 vs. 
8.6 ± 3.2 ml/min/1.73 m2).
Table 2  Baseline characteristics of the 88 incident PD patients
CVD cardiovascular disease, DM diabetes mellitus, BMI body mass 
index, hsCRP high-sensitivity C-reactive protein, TSAT transferrin 
saturation, PTH parathyroid hormone, Ca calcium, P phosphate, RRF 
residual renal function
Men (n = 53) Women (n = 35) p value
Age (years) 57 (44–67) 50 (35–64) NS
CVD (%) 47 26 0.05
DM (%) 34 31 NS
Hypertension (%) 100 94 NS
Body mass (kg) 79.6 ± 11.1 62.1 ± 12.5 0.01
BMI 25.3 ± 3.3 23.3 ± 4.5 0.01
Albumin (g/l) 37.3 ± 3.9 37.06 ± 3.6 NS
hsCRP (mg/l) 3.85 (1.60–8.20) 1.40 (0.70–3.80) 0.01
Iron (mcg/dl) 72.9 ± 24.5 64.7 ± 25.2 NS
Ferritin (ng/ml) 166 (83–211) 140 (73–332) NS
TSAT (%) 27.0 ± 11.2 26.2 ± 12.0 NS
PTH (pg/ml) 330 ± 241 349 ± 257 NS
Ca (mg/dl) 8.92 ± 0.68 8.85 ± 0.76 NS
P (mg/dl) 5.39 ± 1.48 4.71 ± 1.28 0.03
RRF (ml/day) 1423 ± 652 1205 ± 594 NS
Fig. 1  Haemoglobin concentration in 88 incident PD patients
Fig. 2  Dose of ESA; ESA erythropoiesis-stimulating agents in 88 
incident PD patients, BW body weight
 Int Urol Nephrol
1 3
The baseline Hb concentration was lower in women, 
as compared to men, similarly to the situation observed 
in prevalent PD patients, and in the general population; 
Fig. 1. It has to be underlined that, at that time point, ten 
women (29%) and only three men (6%) received ESA as a 
pre-dialysis treatment. The difference in Hb concentration 
persisted throughout the 36-month observation period, var-
ying with time, being most significant after 1 year of dialy-
sis therapy (11.0 ± 1.1 vs. 11.8 ± 1.3 g/dl; p < 0.01). The 
lower Hb level in women was probably the major reason 
for high ESA doses prescribed. The mean doses remained 
fairly stable in men during the 3-year follow-up, while they 
constantly increased in women; Fig. 2. Similarly, ERI, cal-
culated as the ratio between the ESA dose per body weight 
and achieved Hb, was higher in women, as compared to 
men. At baseline, the median ERI equalled 2.81 (1.82–
3.78) in women versus 2.06 (1.37–2.94) in men (p = 0.04). 
In multiple regression analysis, following inclusion of: 
age, co-morbidities, CRP, albumin, iron use, and Kt/V, 
gender was an independent determinant of ERI (b = 0.34; 
p < 0.05). At the end of the 36-month observation period, 
the median ERI was 5.66 (2.85–6.16) in women versus 
3.06 (1.46–4.88) in men, and this difference did not reach 
statistical significance due, mainly, to the low number of 
participants at that time point.
During the first year of the observation period, the 
total Kt/V was significantly higher in women; Fig. 3. This 
was predominantly due to the differences in peritoneal 
Kt/V which was much higher in women, in comparison 
with men. This significant difference persisted through 
the observation period; Fig. 4. The mean peritoneal Kt/V 
throughout the 36 months of observation was 28% higher 
in women, as compared to men.
Haemoglobin concentrations turned out to be related to 
the dialysis adequacy, as assessed by the total Kt/V. After 
12 months of dialysis treatment, the correlation coefficient for 
Hb level and Kt/V equalled r = 0.26; p < 0.05. This associa-
tion was similarly positive throughout the observation period, 
although it did not reach statistical significance at any other 
time point. As in prevalent patients, there was a negative rela-
tionship between the total Kt/V and prescribed ESA dose, 
although not significant at any time point of the follow-up.
It has to be underlined that despite this positive associa-
tion between Kt/V and Hb, and much higher parameters of 
dialysis adequacy in women, they were nevertheless more 
anaemic and required much higher doses of ESA, com-
pared to men.
Discussion
The present study reveals that women treated with PD have 
a lower Hb concentration and are prescribed higher doses 
of ESA, as compared to men. This finding was confirmed 
in two independent groups of prevalent and incident PD 
patients. Moreover, the negative impact of female gender 
on Hb level holds true despite significantly higher total 
Kt/V in women, a parameter positively associated with Hb 
level.
Anaemia constitutes one of the major complications 
of ESRD. It impairs the patient’s physical endurance and 
causes cognitive dysfunction deteriorating quality of life. 
Moreover, it negatively affects cardiac function as it leads 
to left ventricular hypertrophy. If severe, anaemia increases 
the risk of death [7]. Given its detrimental effects, it is 
widely acknowledged that anaemia should be treated and, 
partly, corrected in dialysis patients. The Kidney Disease: 
Improving Global Outcomes (KDIGO) guidelines on anae-
mia management in CKD distinguishes different thresholds 
for men and women to diagnose anaemia [1]. These are 
Fig. 3  Weekly total Kt/V in 88 incident PD patients
Fig. 4  Peritoneal Kt/V in 88 incident PD patients
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less than 13.0 g/dl for men and below 12.0 g/dl for women. 
However, indications for ESA treatment as well as the tar-
get Hb concentrations are set identical for both genders.
In the present evaluation, lower Hb levels were 
observed in both prevalent and incident PD women. Hae-
moglobin was lower despite the fact that men were char-
acterized by an increased baseline CRP and a higher prev-
alence of co-morbidities, two acknowledged risk factors 
for anaemia severity [8]. The findings of the present study 
stay in accordance with previous evaluations in pre-dialy-
sis and haemodialysis patients [4, 9]. In the general popu-
lation, the reference Hb values are different for men and 
women. It is not clear whether, indeed, women require 
less Hb or whether lower concentrations result from iron 
deficiency in view of menstrual blood losses and, perhaps, 
poorer dietary intake [2]. The role of hormonal differ-
ences between genders as a contributing factor has also 
been proposed [2]. Similarly, in haemodialysis patients, 
decreased iron due to menstruations is put forward as the 
main contributor by some authors [10]. However, most 
studies have not confirmed associations between iron sta-
tus and decreased Hb in haemodialysis women [4, 11]. 
According to our knowledge, no studies elucidating this 
issue in PD patients have been reported to date. In the pre-
sent evaluation, iron status was comparable between gen-
ders in the group of incident PD patients, both at baseline 
and during the follow-up.
ESA responsiveness and anaemia correction in dialy-
sis patients depends on numerous factors [12–14]. One of 
the major ones is dialysis adequacy [4]. Uremic toxicity in 
general and/or retention of some direct inhibitors of eryth-
ropoiesis results in aggravated anaemia and poor response 
to ESA treatment. The present study confirmed this asso-
ciation, as the Hb concentrations turned out to be related 
to the total Kt/V in both studied cohorts. Moreover, in the 
prevalent group, Kt/V was negatively associated with ESA 
dose.
In the present evaluation, women were characterized by 
a significantly higher Kt/V, both in the prevalent and inci-
dent group. In incident patients, this was due to signifi-
cantly higher dialysis dose, as reflected by peritoneal Kt/V 
throughout the observation period. Obviously, women, with 
their volume of urea distribution being lower than in men, 
are expected to achieve higher Kt/V when prescribed the 
same dialysis dose [15].
However, in the present study, women, despite reach-
ing higher adequacy parameters, presented with lower Hb 
concentrations, in comparison with men. Perhaps, it is wor-
thy of consideration to aim for a higher Kt/V in women 
in order to alleviate anaemia. On the other hand, it is well 
acknowledged that increasing dialysis dose above the cur-
rently recommended threshold does not lead to improved 
outcome [16].
Having lower Hb concentrations, women receive more 
ESA. It is well acknowledged that ESA treatment can be 
associated with an increase in blood pressure and with an 
enhanced risk of thrombotic complications [17]. Moreover, 
the ESA resistance index (ERI), defined as a ratio between 
the ESA dose and achieved Hb, is associated with a higher 
risk of death in haemodialysis patients [18]. Although stud-
ies in PD patients have not shown such associations [19], 
the question arises as to whether it is necessary to increase 
ESA dose in women in order to achieve Hb concentra-
tions comparable to Hb levels in men. It is a matter of 
debate and, perhaps, future studies to establish whether the 
increased ERI in women, observed in the present evalua-
tion, reflects hyporesponsiveness to ESA or just physiologi-
cally lower Hb concentration. The issue is not only of clini-
cal, but also of financial importance, as increasing the ESA 
doses in women to achieve Hb levels comparable to men is 
an expensive approach.
Our study has its limitations that ought to be under-
lined. First, it is an observational analysis; therefore, 
causal relationships cannot be assessed. Secondly, no 
information on the menstrual status of the studied women 
was obtainable. However, the comparable iron status 
between genders in the studied group suggests that the 
potential impact of menstruation on observed Hb levels is 
negligible. The Registry does not include data potentially 
influencing Hb concentration and/or dialysis adequacy, as 
CRP or BMI. The study has also its strengths. It has been 
conducted on most numerous group of PD patients in 
Poland so far, utilizing data from the national Registry of 
PD. The major findings have been verified and confirmed 
in incident PD patients, in a longitudinal 36-month long 
evaluation.
 In conclusion, we have demonstrated that there is a gen-
der-dependent difference in Hb concentration of patients 
treated with PD with women demonstrating significantly 
lower Hb despite better dialysis adequacy. This results 
in much higher doses of ESA prescribed. Future studies 
should clarify whether this approach is correct.
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